

Varsha Gupta
Manjistha Sengupta
Jaya Prakash
Baishnab Charan Tripathy

Basic and Applied Aspects of Biotechnology

Basic and Applied Aspects of Biotechnology

Varsha Gupta • Manjistha Sengupta
Jaya Prakash • Baishnab Charan Tripathy

Basic and Applied Aspects of Biotechnology



Springer

Varsha Gupta
Institute of Biosciences and
Biotechnology
Chhatrapati Shahu Ji Maharaj University
Kanpur, UP, India

Jaya Prakash
Orthopaedics Unit
Community Health Centre
Kanpur, UP, India

Manjistha Sengupta
George Washington University
Washington DC, USA

Baishnab Charan Tripathy
School of Life sciences
Jawaharlal Nehru University
New Delhi, India

ISBN 978-981-10-0873-3 ISBN 978-981-10-0875-7 (eBook)
DOI 10.1007/978-981-10-0875-7

Library of Congress Control Number: 2016937500

© Springer Science+Business Media Singapore 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by Springer Nature
The registered company is Springer Science+Business Media Singapore Pte Ltd.

Dedicated to teaching fraternity and students

Acknowledgments

We would like to express our heartfelt gratitude to everyone, who has contributed selflessly to the growth and development of science and kept the spirit of knowledge alive. Their quest for knowledge and the reflections of it in the form of writings, publications, books, and other documents have immensely helped us to live that spirit. That immortal spirit of investigation has always been an inspiration for us. Through this book, we hope to pass on that spirit to its readers.

We would like to thank Abhishek Gupta (managing director, i3 Consulting), who has provided his valuable inputs in the chapter on drug design. We would like to acknowledge the contribution of Dr. Kajal Biswas (staff scientist, Mouse Cancer Genetics Program, National Cancer Institute, Frederick, Maryland, USA) for his contribution in the chapter on animal cell culture. We would also thank Meghana and Agastya for spending their time and helping us with the writings and diagrams that could have been well spent on playing and watching cartoon movies. We would also like to thank Neerja, Vishal, Sipahee, Vivek, Gunjan, Sovon, Suruchi, and Meetu for their continued encouragement, support, and cooperation throughout.

The acknowledgment cannot be complete without expressing our gratitude to Dr. Mamta Kapila, Ms. Raman Shukla, Ms. Akanksha, Mr. Magesh Kaarthick, and to the entire Springer team for their cooperation and support.

Last but not the least, through this acknowledgment, we would like to express our gratitude to our family and friends for their immense patience, unfailing cooperation, love and support, and being a constant source of inspiration during the preparation of this project work.

We would like to close by thanking the Almighty for helping us through the entire journey and making this experience enjoyable.

Contents

1	An Introduction to Biotechnology	1
1.1	Introduction.....	2
1.2	Medical Biotechnology	6
1.2.1	Improved Diagnostic and Therapeutic Capabilities	8
1.3	Agricultural Biotechnology.....	9
1.3.1	Food Biotechnology	12
1.4	Environmental Biotechnology.....	12
1.5	Industrial Biotechnology	12
1.5.1	Enzyme Production	13
1.5.2	Exploring Algae for Production of Biofuels.....	13
1.6	Marine or Aquatic Biotechnology.....	14
1.7	Transgenic Animals and Plants	16
1.8	Response to Antibiotic Resistance	16
1.9	The Challenges for the Technology	17
1.9.1	Gene Therapy	17
1.9.2	Designer Babies.....	17
1.9.3	Genetically Modified Food.....	17
1.9.4	Pharmacogenomics.....	17
1.9.5	Tissue Engineering	18
1.10	Ethical Issues.....	18
1.11	Issues Related to Safety	18
1.12	Future of the Technology	19
1.13	Chapter End Summary	19
	References.....	21
2	Fundamentals of Recombinant DNA Technology	23
2.1	Introduction.....	23
2.2	Gene Cloning or Molecular Cloning.....	24
2.3	Restriction Endonucleases (RE).....	24
2.4	Cloning Vectors	24
2.4.1	Plasmids.....	24
2.4.2	Bacteriophage	25
2.4.3	Cosmid.....	25
2.4.4	Bacterial Artificial Chromosome (BAC)	25
2.4.5	Yeast Artificial Chromosome (YAC)	26
2.4.6	Human Artificial Chromosome (HAC).....	26

2.5	<i>lac</i> Operon and Blue-White Screening	26
2.6	Polymerase Chain Reaction (PCR)	27
2.7	Cloning Procedure.....	28
2.8	Library Construction	29
2.8.1	Genomic DNA Library	29
2.8.2	cDNA Library	29
2.9	Site-Directed Mutagenesis (SDM).....	30
2.10	DNA Sequencing.....	31
2.10.1	Dideoxy Chain Termination Method or Sanger's Method.....	31
2.10.2	Maxam–Gilbert Reaction	32
2.10.3	Next-Generation Sequencing (NGS)	33
2.10.4	Pyrosequencing or 454 Sequencing.....	33
2.10.5	Illumina Genome Analyzer.....	33
2.10.6	Applications.....	34
2.11	Genome Editing	35
2.11.1	Double-Stranded DNA Repair Mechanisms	35
2.11.2	Recombineering.....	36
2.11.3	CRISPR/Cas9	36
2.12	Gene Expression and Quantitation.....	38
2.12.1	Real-Time Quantitative PCR (q-PCR)	38
2.12.2	Microarray	41
2.13	RNA Interference or RNAi	42
2.14	Recombinant Protein Expression and Purification.....	43
2.14.1	Protein Expression Systems	43
2.14.2	Promoters.....	46
2.14.3	Selection Markers	48
2.14.4	Affinity Tags and Affinity Purification	49
2.14.5	Expression Vectors.....	51
2.15	Chapter End Summary	55
	References.....	57
3	Animal Cell Culture and Cryopreservation	59
3.1	Introduction	59
3.2	Media Preparation and Sterilization.....	60
3.2.1	Cell Culture Media	60
3.2.2	Sterilization of Cell Culture Media	61
3.3	Culturable Cells.....	62
3.4	Development of Cell Lines	63
3.5	Primary and Established Cell Lines	63
3.6	Techniques of Mammalian Cell Culture	64
3.6.1	Subculturing (Passaging) of Cells	65
3.6.2	Freezing Cells	65
3.6.3	Thawing and Recovering Cells.....	65
3.6.4	Determining Viable Cell Numbers	65
3.6.5	Preparing Cells for Transport	65
3.7	Properties of Cell Lines.....	66
3.8	Passaging	66

3.9	Measurement of Viability and Cytotoxicity	66
3.9.1	Assays Based on Membrane Integrity	66
3.9.2	Assays Based on Radioisotope Incorporation	67
3.9.3	Colorimetric Assays.....	67
3.9.4	Luminescence Assay	67
3.9.5	Apoptosis Assay	67
3.10	Cell Lines and Maintenance.....	67
3.11	Bioreactors for Large-Scale Production of Animal Cells ..	68
3.12	Applications	71
3.12.1	Cancer Research	71
3.12.2	Model System.....	71
3.12.3	Production of Antibodies, Vaccines, and Recombinant Proteins.....	72
3.12.4	Virology	72
3.12.5	Drug Screening and Development and Cytotoxicity Test.....	72
3.12.6	Gene Therapy	72
3.12.7	Replacement of Tissue or Organ	72
3.12.8	Genetic Counseling	72
3.13	Cryopreservation	72
3.13.1	Risks of Cryopreservation	73
3.13.2	Methods to Avoid Risks.....	73
3.13.3	Freezable Tissues.....	73
3.14	Chapter End Summary	73
	References.....	75
4	Production of Recombinant Pharmaceutical Proteins	77
4.1	Introduction.....	77
4.2	Expression of Foreign Gene.....	78
4.2.1	Promoters.....	78
4.2.2	General Considerations for Protein Production..	80
4.2.3	High Protein Expression in the Host	80
4.3	Microbial System for Production of Therapeutic Protein..	81
4.4	Production of Recombinant Protein in Fungal Hosts.....	84
4.5	Production of Recombinant Protein in Insect Cell.....	85
4.6	Production of Recombinant Protein in Mammalian Cell...	86
4.7	Using Human Cells for Protein Production	88
4.8	Transgenics for Protein Production.....	88
4.8.1	Transgenic Animals	88
4.8.2	Transgenic Plants.....	88
4.9	Challenges of Production of Therapeutic Proteins.....	89
4.10	Some Important Biopharmaceuticals	91
4.10.1	Tissue Plasminogen Activator (tPA)	91
4.10.2	Factor VIII	92
4.10.3	Insulin	93
4.10.4	Human Growth Hormone (HGH).....	93
4.10.5	Interferons.....	95
4.10.6	Erythropoietin.....	95

4.10.7	Platelet-Derived Growth Factor (PDGF).....	95
4.10.8	Epidermal Growth Factor (EGF).....	96
4.10.9	Fibroblast Growth Factor (FGF).....	96
4.10.10	Nerve Growth Factor (NGF)	97
4.10.11	Transforming Growth Factor Alpha (TGF- α)....	98
4.10.12	Transforming Growth Factor Beta (TGF- β)	98
4.11	Future Prospects.....	98
4.12	Chapter End Summary	98
	References.....	100
5	Transgenic Animals and Plants.....	103
5.1	Introduction.....	103
5.1.1	Basic Requirements	104
5.2	Preparation of Transgene Construct.....	105
5.3	Production of Transgenic Animals.....	106
5.3.1	Transfer of Transgene in the Animal	107
5.3.2	Pronuclear Microinjection	107
5.3.3	DNA Transfer Through Virus	107
5.3.4	Embryonic Stem Cell Mediated Gene Transfer..	108
5.3.5	Sperm-Mediated Transgenesis.....	109
5.3.6	Somatic Cell Nuclear Transfer	110
5.4	Transient and Stable Insertion of Transgene	112
5.5	Application of Transgenic Animals.....	112
5.5.1	Agricultural Applications	113
5.5.2	Medical Applications.....	113
5.5.3	Industrial Applications.....	115
5.6	Transgenic Plants	116
5.6.1	Transgenic Production in Plants	117
5.7	Ethical Issues in Transgenic Production	120
5.8	Chapter End Summary	120
	References.....	122
6	Genome Sequencing.....	125
6.1	Introduction.....	125
6.2	Human Genome Organization (HUGO)	126
6.2.1	Physical Mapping	130
6.2.2	Genetic Mapping	133
6.2.3	Molecular Markers and Mapping	134
6.3	Completion of Human Genome Project.....	136
6.4	Comparative Genomics	138
6.5	Functional Genomics	138
6.5.1	Genome Annotation.....	138
6.6	Plant Genome Projects	139
6.7	Genome Projects for Model Organisms	139
6.8	Genomics of Pathogens.....	141
6.8.1	Properties of Bacterial Genome.....	141
6.8.2	Understanding Genetic Capacity Required To Become a Pathogen	142

6.8.3	Development of Multiple Drug-Resistant Bacteria.....	143
6.8.4	Hepatitis C Virus.....	143
6.8.5	Influenza Virus.....	144
6.8.6	Human Immunodeficiency Virus (HIV)	146
6.9	Chapter End Summary	147
	References.....	149
7	Pharmacogenomics and Pharmacogenetics.....	151
7.1	Introduction.....	151
7.2	Pharmacogenetics.....	153
7.3	Toxicogenomics	153
7.4	Pharmacodynamics and Pharmacokinetics	153
7.5	Pharmacogenomics	154
7.5.1	Metabolism of Drugs.....	155
7.6	Response of Drug Target.....	159
7.6.1	Other Applications	160
7.7	Theragnostics and Companion Diagnostics	160
7.8	Pharmacogenomic Analysis	162
7.8.1	Candidate Gene Approach.....	162
7.8.2	Whole Genome Approach	162
7.9	Pharmacogenomic Developments and Approvals	162
7.10	Challenges.....	162
7.11	Chemogenomics	163
7.12	Chemical Kinomics.....	163
7.13	Future Prospects	164
7.14	Chapter End Summary	164
	References.....	165
8	Immunology and Medical Microbiology.....	167
8.1	Introduction.....	168
8.2	Introduction to the Immune System.....	168
8.3	Immunology and Medical Microbiology	168
8.4	Innate and Adaptive Immune Responses	169
8.4.1	Innate Immunity	169
8.4.2	Adaptive Immune Responses	174
8.5	Medical Microbiology.....	176
8.6	Gram-Positive and Gram-Negative Infections	177
8.7	Pyrexial Illness	177
8.8	Infections of the Gastrointestinal System	180
8.9	Infections of the Skin and Nail.....	180
8.10	Infections of the Respiratory System	181
8.11	Infections of the Nervous System	183
8.12	Diseases Caused by Prions.....	185
8.13	Sexually Transmitted Diseases (STDs) and Congenital Infection	185
8.13.1	Syphilis	185
8.13.2	Hepatitis B Virus (HBV)	185
8.13.3	Hepatitis A Virus (HAV).....	185

8.13.4	Pelvic Inflammatory Disease (PID).....	186
8.13.5	Genital Herpes	186
8.13.6	Gonococcal and Nongonococcal Urethritis.....	186
8.14	Characterization of Pathogens.....	187
8.14.1	Nucleic Acid Amplification Technology (NAAT)	188
8.15	Chapter End Summary	188
	References.....	190
9	Molecular Diagnostics	191
9.1	Disease Pathology and Clinical Spectrum	191
9.2	Diagnosis of Bacterial, Viral, and Parasitic Diseases.....	192
9.2.1	Serological Tests.....	192
9.3	Nucleic Acid-Mediated Tests	196
9.3.1	PCR and Array-Based Techniques in Diagnosis	196
9.3.2	Loop-Mediated Isothermal Amplification (LAMP)	196
9.3.3	Luminex xMap Technology.....	198
9.3.4	Single Nucleotide Polymorphism and Disease Association	199
9.4	Protein Microarray	200
9.4.1	Proteomic Arrays.....	200
9.4.2	Microspot ELISA and Antibody Arrays	200
9.4.3	Single-Capture Antibody Arrays	200
9.4.4	Antigen Arrays or Reverse Arrays	201
9.4.5	Microarray Western	201
9.4.6	Protein Binder Arrays	201
9.5	Isolation, Processing, and Profiling of Proteins and Other Molecules Associated with Disease	202
9.6	Profiling and Identification of the Protein.....	202
9.6.1	Two-Dimensional Gel Electrophoresis.....	202
9.6.2	Mass Spectrometry (MS).....	202
9.7	Nucleic Acid Amplification Technologies (NAAT)	203
9.8	Ethics in Molecular Diagnosis	203
9.9	Chapter End Summary	203
	References.....	205
10	Diagnosis of Specific Diseases	207
10.1	Introduction	207
10.2	Cancer	207
10.2.1	Mystery of Cancer	208
10.2.2	Cancer: A Multistep Process	208
10.2.3	Tumor Suppressor Genes.....	210
10.2.4	Development of Cancer.....	211
10.2.5	The Hallmarks of Cancer.....	211
10.3	Diagnosis of Cancer	212
10.3.1	Staging of Cancer	212
10.3.2	Computed Tomography (CT)	213

10.3.3	Combined PET/CT	213
10.3.4	Laboratory Test.....	213
10.3.5	Mammograms.....	214
10.3.6	Pap and HPV Testing.....	214
10.3.7	Pathology Report/Biopsy.....	214
10.3.8	Tumor Grade.....	214
10.3.9	Tumor Markers	215
10.4	Diagnosis of Tuberculosis	216
10.4.1	Diagnosis of Latent Infection	218
10.4.2	Mantoux Tuberculin Skin Test.....	219
10.4.3	Chest Radiography	219
10.4.4	Drug Susceptibility Testing	219
10.4.5	Microscopy	219
10.4.6	TB Blood Test (Interferon-Gamma Release Assay-IGRA).....	219
10.4.7	Other Diagnostic Methods.....	221
10.5	Diagnosis of Malaria	223
10.5.1	Laboratory Diagnosis Method	223
10.5.2	Serology: Indirect Fluorescence Antibody (IFA) Test.....	224
10.5.3	Rapid Diagnostic Test (RDT)	224
10.5.4	Molecular Techniques.....	224
10.5.5	Drug Resistance Tests.....	226
10.6	Diagnosis of Acquired Immunodeficiency Syndrome (AIDS)	226
10.6.1	Tests Detecting HIV-Specific Antibodies	226
10.6.2	Rapid Test	228
10.6.3	Viral Load Test	229
10.6.4	Peripheral Blood Mononuclear Cell Culture	229
10.7	Chapter End Summary	229
	References.....	232
11	Molecular Therapeutics.....	235
11.1	Introduction.....	235
11.2	Immunostimulants.....	235
11.3	Immunosuppressors.....	236
11.4	Interferons	237
11.5	Proteins as Therapeutic Agent.....	237
11.5.1	Group I.....	239
11.5.2	Group II	239
11.5.3	Group III.....	244
11.5.4	Group IV	245
11.6	Monoclonal Antibodies	245
11.6.1	Diagnosis of Pathogen	249
11.6.2	Viral Diseases	249
11.7	Catalytic Antibodies or Abzymes.....	249
11.8	Antibodies as In Vitro and In Vivo Probes	250

11.9	Cancer Detection and Therapy	250
11.9.1	Cancer Therapeutics	250
11.9.2	Cancer–Tumor Immunology	252
11.9.3	Tumor Antigens	252
11.9.4	Immune Response to Tumors and Tumor Evasion of the Immune System	252
11.9.5	Cancer Immunotherapy	252
11.9.6	Antibody Therapy	253
11.10	Cancer Vaccines	255
11.11	Advancements in Therapy of AIDS (Human Immunodeficiency Virus)	256
11.12	Chapter End Summary	259
	References.....	260
12	Rational Drug Designing	263
12.1	Introduction	264
12.2	Modes of Drug Discovery	264
12.3	Lead Compound Identification and Optimization.....	265
12.4	Structure-Based Drug Design	265
12.4.1	Cloning a Drug Target	266
12.4.2	X-Ray Crystallography	266
12.4.3	Nuclear Magnetic Resonance (NMR) Spectroscopy	267
12.4.4	Comparative or Homology Modeling.....	268
12.4.5	Threading/Fold Recognition	270
12.4.6	Ab Initio Method	270
12.5	Ligand-Based Drug Design.....	271
12.6	Drug Targets	271
12.6.1	Identification of Target Site	271
12.7	Identification of Lead for Drug Designing	271
12.7.1	Computer-Aided Drug Designing (CADD)	271
12.8	Docking Method.....	272
12.8.1	Importance of Understanding Solution and Flexible Ligand	272
12.8.2	Algorithms Underlying Various Docking Programs	273
12.9	De Novo Generation	274
12.10	Drug Lead Evaluation	275
12.11	Drug Discovery	275
12.12	Chapter End Summary	276
	References.....	278
13	Drug Targeting and Delivery	279
13.1	Introduction	280
13.2	Biological Barriers to Drug Delivery	280
13.2.1	Skin Barriers	280
13.2.2	Mucus and Surfactants	281
13.2.3	Blood–Brain Barrier (BBB)	282

13.2.4	Microbial Biofilm	283
13.2.5	Drug Efflux Pumps.....	284
13.3	Drug Delivery System (DDS)	285
13.3.1	Nanoparticle-Mediated Delivery	286
13.3.2	Cells as Drug Delivery Vehicle.....	290
13.3.3	Extracellular Vesicles (EV).....	292
13.4	Drug Targeting	293
13.4.1	Passive Targeting	293
13.4.2	Active Targeting.....	293
13.5	Application in Diseases.....	296
13.5.1	Drug Delivery to the Brain	296
13.5.2	Targeted Therapies for Cancer.....	297
13.5.3	Targeted Therapies for Viral Infections	298
13.6	Side Effects of Targeted Therapies.....	300
13.7	Chapter End Summary	301
	References.....	302
14	Vaccine	305
14.1	Introduction.....	306
14.2	Vaccine Technology: Role and Properties of Adjuvants ...	306
14.3	Prophylaxis.....	308
14.3.1	Passive and Active Vaccination.....	309
14.3.2	Routes of Vaccine Administration	310
14.4	Attenuated Vaccine.....	312
14.5	Inactivated/Killed Vaccine.....	313
14.6	Subunit Vaccines	313
14.6.1	Capsular Polysaccharides	315
14.6.2	Viral Glycoproteins	315
14.7	Synthetic Peptides as Vaccine	315
14.8	Conjugate Vaccines	315
14.9	DNA Vaccines	316
14.10	Edible Vaccines	316
14.11	Vaccines for Cancer.....	318
14.12	Generations of Vaccines	319
14.13	Reverse Vaccinology or Genome-Based Vaccine Development.....	320
14.13.1	Reverse Vaccinology.....	320
14.14	Chapter End Summary	320
	References.....	322
15	Embryo Transfer Technology.....	323
15.1	Introduction	323
15.2	Infertility	323
15.2.1	Male Infertility.....	324
15.2.2	Female Infertility	324
15.3	Indications for IVF.....	324
15.4	Intracytoplasmic Sperm Injection (ICSI)	324
15.4.1	Concerns About ICSI.....	325

15.5	Technique of IVF	325
15.5.1	Superovulation.....	326
15.5.2	Retrieval of Oocyte and IVF.....	326
15.5.3	Drawbacks of IVF	326
15.5.4	Risk of Ovarian Hyperstimulation Syndrome	327
15.6	Developments in Assisted Reproductive Technology	327
15.6.1	Assisted Hatching.....	327
15.6.2	Preimplantation Genetic Diagnosis	328
15.6.3	In Vitro Maturation (IVM) of Oocytes	328
15.6.4	Cryopreservation of Oocyte.....	329
15.7	Ethical Issues in IVF	329
15.8	Future Prospects	330
15.9	Chapter End Summary	330
	References.....	331
16	Stem Cell Biology and Its Clinical Application	333
16.1	Introduction.....	333
16.2	Stem Cell Classification	334
16.2.1	Embryonic Stem Cells.....	335
16.2.2	Adult Stem Cell	336
16.2.3	Induced Pluripotency.....	336
16.3	Stem Cell Plasticity	338
16.4	Stem Cell Division and Differentiation.....	338
16.5	Therapeutic Roles of Stem Cells.....	340
16.6	Tissue Development and Disease	340
16.7	Stem Cell Replacement	341
16.8	Regenerative Therapies	341
16.9	Disease-Specific Stem Cell Approach.....	342
16.9.1	Nervous System.....	343
16.9.2	Liver.....	343
16.9.3	Heart Disease.....	343
16.10	Controversy Surrounding Stem Cell Research.....	345
16.11	Chapter End Summary	346
	References.....	348
17	Gene Therapy	351
17.1	Introduction.....	351
17.2	Germline Therapy	352
17.3	Somatic Cell Therapy.....	353
17.4	Intracellular Barriers to Gene Delivery	354
17.5	Virus-Mediated Gene Transfer	354
17.6	Nonviral Vectors.....	356
17.7	Overview of Inherited and Acquired Diseases for Gene Therapy	356
17.8	Attempts at Human Gene Therapy.....	358
17.8.1	Gene Therapy for Cancer	360
17.8.2	Gene Therapy and the Central Nervous System.....	362
17.8.3	Gene Therapy and Orthopedics	362

17.9	Gene Doping	363
17.10	Recent Developments in Gene Therapy	364
17.10.1	RNA Interference Technology.....	364
17.10.2	Therapeutic Ribozyme.....	364
17.10.3	Antisense Oligonucleotides	365
17.10.4	Zinc Finger Nuclease.....	365
17.11	Risks and Problems Involved in Gene Therapy	365
17.12	Potential of Gene Therapy.....	366
17.13	Chapter End Summary	368
	References.....	370
18	Forensic Medicine	373
18.1	Introduction.....	373
18.2	Collection of Specimen.....	374
18.2.1	Physical Examination	374
18.2.2	Blood Groups.....	374
18.2.3	Spectroscopic Analysis.....	374
18.2.4	Electrophoretic Separation	375
18.2.5	Semen	375
18.2.6	Saliva	375
18.2.7	Other Body Fluids and Components	376
18.3	DNA Fingerprinting	376
18.3.1	Slippage of Replication	376
18.3.2	Satellite DNA.....	377
18.3.3	Single Nucleotide Polymorphism.....	378
18.3.4	Restriction Fragment Length Polymorphism (RFLP)	378
18.4	DNA Profiling	379
18.4.1	Multiplex Polymerase Chain Reaction (PCR).....	379
18.5	Future Prospects	382
18.5.1	RNA Profiling	382
18.5.2	DNA Methylation	383
18.6	Chapter End Summary	383
	References.....	384
19	Environmental Biotechnology	385
19.1	Introduction.....	385
19.2	Pollution	386
19.2.1	Greenhouse Effect	386
19.2.2	Water Pollution	387
19.2.3	Air Pollution	391
19.2.4	Noise Pollution	391
19.2.5	Electromagnetic Pollution	391
19.3	Environmental Monitoring	392
19.3.1	Water Quality Monitoring	392
19.3.2	Air Quality Monitoring.....	392
19.3.3	Biomarker/Bioindicator	392
19.3.4	Biosensors.....	393

19.3.5	Nanoparticle-Based Detection.....	393
19.3.6	Continuous Emissions Monitoring System (CEMS): Used for Air Quality Monitoring	394
19.3.7	Particulate Matter Sampler	394
19.3.8	Portable Emission Measurement System (PEMS)	395
19.4	Biotechnology and Environment.....	395
19.5	Bioremediation.....	395
19.5.1	Need for Bioremediation	395
19.5.2	Microorganisms Involved in Bioremediation	395
19.5.3	Factors Affecting Bioremediation.....	396
19.5.4	Process of Bioremediation.....	397
19.5.5	Types of Bioremediation	397
19.5.6	In Situ Bioremediation	398
19.5.7	Ex Situ Bioremediation	398
19.5.8	Phytoremediation.....	400
19.5.9	Mode of Phyto-tolerance	401
19.5.10	Uses of Bioremediation	402
19.5.11	Advantages of Bioremediation	405
19.5.12	Limitations of Bioremediation	407
19.6	Integrated Pest Management and Biopesticides.....	407
19.6.1	Biopesticides.....	408
19.7	Role of Biotechnology in Innovative Products	410
19.8	Chapter End Summary	411
	References.....	412
20	Plant Biotechnology and Agriculture	415
20.1	Introduction	416
20.2	Conventional Plant Breeding.....	417
20.2.1	Selective Crossbreeding.....	417
20.2.2	Classical Breeding with Induced Mutation	418
20.2.3	Hybrid Varieties and Their Applications	421
20.2.4	Limitations of Conventional Plant Breeding	421
20.3	Transgenics in Crop Improvement	422
20.3.1	New and Future Initiatives in Crop Genetic Engineering.....	423
20.4	Genetic Marker-Assisted Breeding	424
20.5	Tissue Culture and Plant Regeneration	425
20.5.1	Basic Introduction to Cell Culture.....	426
20.5.2	Culture of Cells.....	427
20.5.3	Plant Tissue Culture Techniques.....	428
20.6	Applications of Agricultural Biotechnology	429
20.6.1	Applications of Plant Tissue Culture	429
20.6.2	Production of Biopharmaceuticals	430
20.6.3	Production of Secondary Metabolites	431
20.6.4	Production of Stress-Tolerant Crops.....	432
20.6.5	Production of Insect-/Pest-Resistant Crops	432

20.6.6	Protease Inhibitors and Pest Resistance	435
20.6.7	Production of Herbicide-Resistant Crops.....	436
20.6.8	Production of Virus-Resistant Crops	437
20.6.9	Production of Biofuel and Biodiesel	437
20.6.10	Improved Nutritional Traits by Biotechnological Interventions.....	438
20.6.11	Removal/Reduction of Antinutrients, Allergens, and Toxins	441
20.6.12	Production of Perfumes and Scent	442
20.6.13	Phytoremediation.....	442
20.7	Germplasm Conservation and Cryopreservation	442
20.8	GMOs and Risk Assessment.....	443
20.9	Safety Assessment.....	446
20.10	Future Prospects	446
20.11	Conclusions.....	447
20.12	Chapter End Summary	447
	References.....	450
21	Tissue Engineering and Artificial Organ	453
21.1	Introduction to Tissue Engineering	453
21.2	Source of Tissue/Cells.....	454
21.3	Requirements of Tissue Engineering	454
21.3.1	Cells.....	455
21.3.2	Growth Factors	456
21.3.3	Polymers	456
21.4	Properties of Biomaterial	461
21.5	Designing of Scaffolds.....	462
21.5.1	Fabrication Methods	462
21.5.2	Modern Fabrication Methods	465
21.6	Assembly Methods.....	467
21.6.1	Tissue Culture.....	467
21.6.2	Bioreactors.....	468
21.7	Artificial Organs.....	468
21.8	Achievements	468
21.9	Industry Challenges.....	470
21.10	The Future	470
21.11	Chapter End Summary	471
	References.....	472
22	Lifestyle, Stress, and Disorders.....	475
22.1	Introduction.....	476
22.2	Stress	477
22.3	Mechanism of Stress-Induced Infection Susceptibility.....	478
22.4	Management of Lifestyle-Related Diseases.....	479
22.5	Related Diseases.....	480
22.6	Chapter End Summary	484
	References.....	486

23 Intellectual Property Rights.....	487
23.1 Introduction.....	488
23.2 Trade-Related International Agreements	488
23.2.1 General Agreement on Tariffs and Trade (GATT)	488
23.2.2 World Trade Organization (WTO).....	489
23.2.3 World Intellectual Property Organization (WIPO)	489
23.2.4 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)	490
23.2.5 Paris Convention for Protection of Industrial Property.....	490
23.2.6 Patent Cooperation Treaty (PCT)	491
23.2.7 Budapest Treaty	491
23.2.8 Patent Law Treaty (PLT).....	491
23.2.9 Mailbox Provision	491
23.2.10 Exclusive Marketing Rights (EMR)	491
23.2.11 Union for the Protection of New Varieties of Plants (UPOV).....	492
23.3 Types of Intellectual Property and Rights	492
23.3.1 Industrial Property	492
23.3.2 Copyright.....	496
23.4 Intellectual Property Rights: Indian Scenario	496
23.4.1 Indian Patents Act, 1970.....	496
23.4.2 Plant Breeders' Rights or Protection of Plant Varieties and Farmers' Rights Act.....	497
23.5 Chapter End Summary	499
References.....	501
24 Biosafety and Bioethics.....	503
24.1 Introduction.....	503
24.2 Biosafety and Biorisk.....	504
24.2.1 Assessment of Risk.....	505
24.2.2 Biohazards	505
24.2.3 Laboratory Biosafety	506
24.2.4 High and Maximum Containment	507
24.2.5 The Importance of Biocontainment Laboratories	508
24.3 Biotechnology and Bioethics	508
24.3.1 Analyzing Ethical Issues	509
24.3.2 Ethics and Ethical Theories	510
24.4 Ethical Issues in Transgenic Animal Production.....	511
24.5 Genetically Modified Crops and Bioethics	512
24.5.1 Genetically Modified Organisms and Environment.....	512

24.6	Bioethics and Reproductive Technology.....	514
24.7	Stem Cells and Bioethics	515
24.8	Human Cloning and Bioethics	516
24.9	Impact of Biotechnology on Society: Future Prospects.....	516
24.10	Chapter End Summary	517
	References.....	518
	Index.....	521

About the Authors

Varsha Gupta, Ph.D. is working as Assistant Professor in Biotechnology Department, Chhatrapati Shahu Ji Maharaj University, Kanpur. She is specialized in genomics and proteomics techniques. Her research group is presently focusing on molecular diagnostics of autoimmune and orthopaedics disorders like rheumatoid arthritis, psoriatic arthritic, diabetes mellitus and osteoarthritis.

Her publications are:

1. Patel SL, Kumar V, Mishra R, Chandra V, Negi MPS, Tripathy BC, Prakash J and Gupta Varsha (2014) Effectiveness of methotrexate therapy with occasional corticosteroid in rheumatoid arthritis. Current Orthopaedics Practice.
2. Prakash J, Singh H, *Gupta Varsha* (2012) Evaluating arthroscopic debridement as a surgical option for patients with differing grades of knee osteoarthritis. Current Orthopaedics Practice. 23: 218-220.
3. Mishra R, Singh A, Chandra V, Negi MPS, Tripathy BC, Prakash J, and Gupta Varsha (2011) A comparative analysis of serological parameters and oxidative stress in Osteoarthritis and Rheumatoid arthritis. Accepted for publication in Rheumatology International (Clinical and Experimental Investigations) DOI: 10.1007/s00296-011-1964-1.
4. Gaur R, Sethy NK, Choudhary S, Shokeen B, *Gupta Varsha*, Bhatia S. (2011) Advancing the STMS genomic resources for defining new locations on the intra specific genetic linkage map of chickpea (*Cicerarietinum L.*). BMC Genomics. Feb 17;12:117.

Manjistha Sengupta, Ph.D. research interests broadly include the study of pathogenesis of infectious and autoimmune diseases. Her research encompasses several aspects of human health such as establishment of infection by pathogenic micro-organisms, mechanism of disease progression, multidrug resistance and study of virulence factors associated with clinically relevant pathogens, for example *Candida albicans* and *Vibrio cholerae*. Her studies include mechanisms of low copy virulence plasmid inheritance and maintenance in *E.coli*. She is currently studying autoimmune neuromuscular disorder myasthenia gravis at George Washington University, Washington, DC.

1. Manjistha Sengupta, Amrita Cheema, Henry Kaminski, Linda Kusner and The Muscle Study Group (2014). Serum Metabolomic Response of

- Myasthenia Gravis Patients to Chronic Prednisone Treatment. PLoS ONE. 9(7): e102635. doi:10.1371/journal.pone.0102635.
2. James A Sawitzke, Brenda Youngren, Lynn C. Thomason, Teresa Baker, Manjistha Sengupta, Donald Court and Stuart Austin (2012). The segregation of E.coliminichromosomes constructed in vivo by recombineering. Plasmid. 67: 148–54.
 3. Manjistha Sengupta and Stuart Austin (2011). The prevalence and significance of plasmid maintenance functions in virulence plasmids of pathogenic bacteria. Infection and Immunity. 79: 2502–9.
 4. Swagata Ghosh, Hanumanta Rao, Manjistha Sengupta, Sujit Bhattacharya, AsisDatta (2011). Two gene clusters coordinate for a functional N-acetylglucosamine catabolic pathway in Vibrio cholerae. Molecular Microbiology. 80: 1549–60.

Jaya Prakash, M.B.B.S., D.Ortho, D.N.B. (sec) Orthopaedics is senior medical officer, orthopaedic surgeon working with Uttar Pradesh Health Services. He is specialized in trauma and arthroscopic surgery. He handles various aspects of orthopaedic surgeries and disorders including autoimmune diseases like rheumatoid and psoriatic arthritic. He has contributed immensely for welfare of patients and has been awarded Kannauj Ratna for working selflessly for society and people. His some of the contributions are:

1. Patel SL, Kumar V, Mishra R, Chandra V, Negi MPS, Tripathy BC, Prakash J and Gupta Varsha (2014) Effectiveness of methotrexate therapy with occasional corticosteroid in rheumatoid arthritis. Current Orthopaedics Practice.
2. Prakash J, Singh H, Gupta Varsha (2012) Evaluating arthroscopic debridement as a surgical option for patients with differing grades of knee osteoarthritis. Current Orthopaedics Practice. 23: 218–220.
3. Mishra R, Singh A, Chandra V, Negi MPS, Tripathy BC, Prakash J, and Gupta Varsha (2011) A comparative analysis of serological parameters and oxidative stress in Osteoarthritis and Rheumatoid arthritis. Accepted for publication in Rheumatology International (Clinical and Experimental Investigations) DOI: 10.1007/s00296-011-1964-1.

Baishnab Charan Tripathy, Ph.D. is presently Dean of School of Life Sciences, Jawaharlal Nehru University, New Delhi. He has worked as Vice-Chancellor, Ravenshaw University, Cuttack, Odisha, from November 25, 2011–November 24, 2014. He has received several honours and awards for his contributions in the field of photobiology. He is distinguished scientist who has worked for NASA's Space Biology Project. He is visiting scientist at many international universities and institutes. He has organized many national and international conferences and is member of several academic bodies of JNU. More than 20 students have got their PhD degree under his expert guidance and supervision. He has got a patent to his credit (US2009/0291476 A1) for overexpressing gene of protochlorophyllide oxidoreductase C for imparting resistance in the plants against biotic and abiotic stresses. He has served as reviewer to several prestigious national and international journals like

“The Plant cell,” “Plant physiology” to name a few. He is the reviewer for proposals submitted to National Science Foundation, USA; Hungarian Academy of Sciences; and German Science Foundation. He has 80 publications in peer-reviewed high-impact journals and co-authored two books with Springer, Dordrecht, The Netherlands.

Some of his publications after 2010 are:

1. Leelavathi, S, Bhardwaj, A., Kumar, S., Dass, A, Pathak, R, Pandey, SS, Tripathy, BC, Padmalatha, KV, Dhandapani, G, Kanakachari, M, Ananda Kumar, P, Cellai, R, Reddy, VS (2011) Genome-wide transcriptome and proteome analyses of tobacco psaA and psbA deletion mutants. *Plant Mol Biol.* 76: 407–423.
2. Pattanayak, G. K., Tripathy, BC (2011) Overexpression of protochlorophyllide oxidoreductase C regulates oxidative stress in Arabidopsis. *Plos One* (Published online October, 2011).
3. Biswal AK, Pattanayak GK, Pandey SS, Leelavathi S, Reddy VS, Govindjee, Tripathy BC (2012). Light intensity-dependent modulation of chlorophyll b biosynthesis and photosynthesis by overexpression of chlorophyllide a oxygenase in tobacco. *Plant Physiol*

Abstract

Biotechnology is multidisciplinary field which has major impact on our lives. The technology is known since years which involves working with cells or cell-derived molecules for various applications. It has wide range of uses and is termed “technology of hope” which impact human health, well being of other life forms and our environment. It has revolutionized diagnostics and therapeutics; however, the major challenges to the human beings have been threats posed by deadly virus infections as avian flu, Chikungunya, Ebola, Influenza A, SARS, West Nile, and the latest Zika virus. Personalized medicine is increasingly recognized in healthcare system. In this chapter, the readers would understand the applications of biotechnology in human health care system. It has also impacted the environment which is loaded by toxic compounds due to human industrialization and urbanization. Bioremediation process utilizes use of natural or recombinant organisms for the cleanup of environmental toxic pollutants. The development of insect and pest resistant crops and herbicide tolerant crops has greatly reduced the environmental load of toxic insecticides and pesticides. The increase in crop productivity for solving world food and feed problem is addressed in agricultural biotechnology. The technological advancements have focused on development of alternate, renewable, and sustainable energy sources for production of biofuels. Marine biotechnology explores the products which can be obtained from aquatic organisms. As with every research area, the field of biotechnology is associated with many ethical issues and unseen fears. These are important in defining laws governing the feasibility and approval for the conduct of particular research.

1.1 Introduction

The term “biotechnology” was coined by a Hungarian engineer Karl Ereky, in 1919, to refer to the science and methods that permit products to be produced from raw materials with the aid of living organisms. Biotechnology is a diverse field which involves either working with living cells or using molecules derived from them for applications oriented toward human welfare using varied types of tools and technologies. It is an amalgamation of biological science with engineering whereby living organisms or cells or parts are used for production of products and services. The main subfields of biotechnology are medical (red) biotechnology, agricultural (green) biotechnology, industrial (white) biotechnology, marine (blue) biotechnology, food biotechnology, and environmental biotechnology (Fig. 1.1.). In this chapter the readers will understand the potential applications of biotechnology in several fields like production of medicines; diagnostics; therapeutics like monoclonal antibodies, stem cells, and gene therapy; agricultural biotechnology;

pollution control (bioremediation); industrial and marine biotechnology; and biomaterials, as well as the ethical and safety issues associated with some of the products.

The biotechnology came into being centuries ago when plants and animals began to be selectively bred and microorganisms were used to make beer, wine, cheese, and bread. However, the field gradually evolved, and presently it is the use or manipulation of living organisms to produce beneficiary substances which may have medical, agricultural, and/or industrial utilization. Conventional biotechnology is referred to as the technique that makes use of living organism for specific purposes as bread/cheese making, whereas modern biotechnology deals with the technique that makes use of cellular molecules like DNA, monoclonal antibodies, biologics, etc. Before we go into technical advances of DNA and thus recombinant DNA technology, let us have the basic understanding about DNA and its function.

The foundation of biotechnology was laid down after the discovery of structure of DNA in

Fig. 1.1 Major applications of biotechnology in different areas and some of their important products

